Ann: Phase 3 Osteoarthritis Clinical Trial Commences, page-243

There is another Australian stock in suspension on the verge of announcing results in orthopedics (tendons). I cannot name, as even though its results will have effect for CYP, I will get removed for cross promoting. It also treats OA, but with chondrocytes, not mesenchymal and arguably could be a complimentary competitor to CYP - the trial is in tendons, but at least in orthopedics. Very different approach too (autologous cells).

The point is, a positive result, and I am very confident of a positive result having had the procedure, could garner interest in the sector. They are phase 2 studies, but not insiginficant with good RCT data. I haven't often argued a floating tide raises all boats.....